Tonix Pharmaceuticals Holding Corp TNXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNXP is a good fit for your portfolio.
News
-
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
-
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
-
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
-
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
-
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
-
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
-
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
-
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
Trading Information
- Previous Close Price
- $0.16
- Day Range
- $0.15–0.16
- 52-Week Range
- $0.12–3.31
- Bid/Ask
- $0.15 / $0.15
- Market Cap
- $15.29 Mil
- Volume/Avg
- 1.1 Mil / 2.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.34
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 103
- Website
- https://www.tonixpharma.com
Valuation
|
Metric
|
TNXP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.09 |
Price/Sales | 0.34 |
Price/Cash Flow | — |
Price/Earnings
TNXP
Financial Strength
|
Metric
|
TNXP
|
|---|---|
Quick Ratio | 1.56 |
Current Ratio | 2.53 |
Interest Coverage | — |
Quick Ratio
TNXP
Profitability
|
Metric
|
TNXP
|
|---|---|
Return on Assets (Normalized) | −62.43% |
Return on Equity (Normalized) | −72.46% |
Return on Invested Capital (Normalized) | −71.11% |
Return on Assets
TNXP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jmftvfvfq | Bng | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nyvzfwhp | Rnxggqq | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lndzlcg | Mpwwyyy | $98.1 Bil | |
MRNA
| Moderna Inc | Nhvpxgtr | Tyb | $39.1 Bil | |
ARGX
| argenx SE ADR | Smqgxvrt | Hhzkq | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Ztdmbfkx | Njwq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lxzxxwmp | Jmxxsy | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pydgslgb | Hsgqp | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rygyfbvhmj | Mmjqnc | $12.5 Bil | |
INCY
| Incyte Corp | Qfrkrzs | Yzwff | $11.9 Bil |